STOCK TITAN

Organigram to Report Third Quarter 2022 Results on July 14, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Organigram Holdings Inc. (NASDAQ: OGI) announced it will report its earnings results for Q3 2022, ending May 31, 2022, on July 14, 2022, before the market opens. A conference call is scheduled for the same day at 8:00 am Eastern Time to discuss the results. Interested participants can register through provided links and access the live call or a replay later. Organigram, a licensed producer of cannabis and cannabis-derived products in Canada, focuses on high-quality products for patients and adult recreational consumers.

Positive
  • None.
Negative
  • None.

TORONTO--(BUSINESS WIRE)-- Organigram Holdings Inc. (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (together, the “Company” or “Organigram”), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter 2022 ended May 31, 2022 on Thursday, July 14, 2022 before market open.

The Company will host a conference call to discuss its results with details as follows:

Date: July 14, 2022
Time: 8:00 am Eastern Time

To register for the conference call, please use this link:
https://conferencingportals.com/event/RUyBPhzX

To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes before the start of the call. After registering, a confirmation will be sent through email, including dial in details and unique conference call codes for entry. Registration is open through the live call.

To access the webcast:
https://events.q4inc.com/attendee/915133557

A replay of the webcast will be available within 24 hours after the conclusion of the call at https://www.organigram.ca/investors and will be archived for a period of 90 days following the call.

About Organigram Holdings Inc.

Organigram Holdings Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly-owned subsidiaries include: Organigram Inc. and Laurentian Organic Inc., licensed producers of cannabis and cannabis-derived products in Canada, and The Edibles and Infusions Corporation, a licensed manufacturer of cannabis-infused soft chews in Canada.

Organigram is focused on producing high-quality, cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Laurentian, Tremblant Cannabis and Trailblazer. Organigram operates facilities in Moncton, New Brunswick and Lac-Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).

This news release contains forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words and phrases or state that certain actions, events, or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, events, performance or achievements of Organigram to differ materially from current expectations or future results, performance or achievements expressed or implied by the forward-looking information contained in this news release. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information include factors and risks as disclosed in the Company’s most recent annual information form, management’s discussion and analysis and other Company documents filed from time to time on SEDAR (see www.sedar.com) and filed or furnished to the Securities and Exchange Commission on EDGAR (see www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Although the Company believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information included in this news release are made as of the date of this news release and the Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

For media inquiries:



Paolo De Luca

Chief Strategy Officer

paolo.deluca@organigram.ca



For investor inquiries:

investors@organigram.ca

Source: Organigram Holdings Inc.

FAQ

When will Organigram Holdings report its Q3 2022 earnings results?

Organigram Holdings will report its Q3 2022 earnings results on July 14, 2022.

What time is the conference call for Organigram's Q3 2022 earnings?

The conference call for Organigram's Q3 2022 earnings is scheduled for 8:00 am Eastern Time on July 14, 2022.

How can I register for Organigram's earnings conference call?

You can register for Organigram's earnings conference call via the registration link provided in their press release.

Where can I find the replay of Organigram's Q3 2022 earnings call?

The replay of Organigram's Q3 2022 earnings call will be available within 24 hours on their investor relations website.

What is Organigram Holdings' stock symbol?

Organigram Holdings' stock symbol is OGI.

Organigram Holdings Inc. Common Shares

NASDAQ:OGI

OGI Rankings

OGI Latest News

OGI Stock Data

166.12M
75.87M
31.32%
9.73%
2.11%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Toronto